Generation of neurons by reprogramming of oligodendrocytes and oligodendrocyte precursor cells
AssigneeThe University of North Carolina at Chapel Hill
InventorsThomas McCown, Marc Weinberg
Life of this patent
Estimating the term…
Abstract
The invention relates to products and methods for transdifferentiating oligodendrocytes and/or oligodendrocyte precursor cells to neurons. The invention further relates to methods of treating central nervous system disorders and conditions.
Claims20
A method of transdifferentiating an oligodendrocyte or an oligodendrocyte precursor cell to a neuron, comprising contacting the oligodendrocyte or oligodendrocyte precursor cell with a composition comprising an antisense or interfering nucleotide sequence that hybridizes to a polynucleotide encoding a polypyrimidine-tract-binding protein 1 (PTBP1), or an expression vector encoding the antisense or interfering nucleotide sequence, wherein the antisense or interfering nucleotide sequence comprises a nucleotide sequence with at least 85% sequence identity to SEQ ID NO:
- 4 and/or a nucleotide sequence with at least 85% sequence identity to the complement of SEQ ID NO:
- 4, thereby transdifferentiating the oligodendrocyte or oligodendrocyte precursor cell to a neuron.
A method of attenuating expression of PTBP1 in a cell, comprising contacting the cell with a composition comprising an antisense or interfering nucleotide sequence that hybridizes to a polynucleotide encoding PTBP1, or an expression vector encoding the antisense or interfering nucleotide sequence, wherein the antisense or interfering nucleotide sequence comprises a nucleotide sequence with at least 85% sequence identity to SEQ ID NO:
- 4 and/or a nucleotide sequence with at least 85% sequence identity to the complement of SEQ ID NO:
- 4, thereby attenuating the expression of PTBP1.
A method of treating a central nervous system disorder or condition responsive to an increase in the number of neurons in a subject in need thereof, the method comprising delivering to the brain a polynucleotide encoding an antisense or interfering nucleotide sequence that hybridizes to a polynucleotide encoding a PTBP1, or a vector comprising the polynucleotide, wherein the antisense or interfering nucleotide sequence comprises a nucleotide sequence with at least 85% sequence identity to SEQ ID NO:
- 4 and/or a nucleotide sequence with at least 85% sequence identity to the complement of SEQ ID NO:
- 4, thereby treating the central nervous system disorder or condition.
Dependencies are inferred from the claim text.